Ahmed F. Ibrahim, MBA’s Post

Fascinating changes happening in the CRO world due to a variety of causes, many specific to the individual company. Still on the whole, the reduction in early phase pharma research is having an immediate impact on the companies in the field. The question is, will we see a long-term impact with fewer novel, lifesaving drugs making it to the market?

🔬 𝟐𝟎𝟐𝟒: 𝐀 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐘𝐞𝐚𝐫 𝐟𝐨𝐫 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐂𝐑𝐎𝐬 This year has been an uphill battle for preclinical CROs. From increasing regulatory complexities and economic pressures to supply chain disruptions, the industry has faced significant hurdles. Many are feeling the strain of balancing cutting-edge research with 𝐭𝐢𝐠𝐡𝐭𝐞𝐧𝐞𝐝 𝐛𝐮𝐝𝐠𝐞𝐭𝐬 and shifting timelines. As the industry adapts to these challenges, 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 will play a critical role in sustaining growth. Let’s continue 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐧𝐠 each to continue advancing science for the greater good. 💡🌟 𝐈𝐭'𝐬 𝐚 𝐭𝐢𝐦𝐞 𝐭𝐨 𝐫𝐞𝐟𝐥𝐞𝐜𝐭, 𝐫𝐞𝐜𝐚𝐥𝐢𝐛𝐫𝐚𝐭𝐞, 𝐚𝐧𝐝 𝐫𝐞𝐦𝐚𝐢𝐧 𝐫𝐞𝐬𝐢𝐥𝐢𝐞𝐧𝐭. #CROs #Innovation #Resilience #Partnerships #Biotech

Interesting post here from Vincent Ling on one of the lesser talked about ripple effects of the current life sciences funding landscape. While 2024 has had its share of difficulties, there's still a silver lining for CROs. Rising costs are making in-house drug development increasingly unsustainable. This reality is fueling the growth of the CRO sector. In fact, according to Fortune Business Insights, the CRO market is projected to expand from $86.33 billion in 2024 to $175.46 billion by 2032. That’s a compounded annual growth rate of 9.3%. And the good news doesn’t stop there.  WCG reports that the demand for new clinical trials is now surpassing the number of available research sites.  This mismatch is creating opportunities for CROs to step in and bridge the gap. Add to that the accelerating integration of artificial intelligence and machine learning, and the future of the CRO industry looks even brighter. It’s clear: despite the hurdles, a resurgence is on the horizon for CROs.

Tale of Woe for Pharma CROs. Since January, hardship has hit the preclinical contract research labs - Evotec, Wuxi Apptec, and Gingko Bioworks. All down 60% to 80% in this short time span. Charles River still holding stable. Surprising that Wuxi Apptec, even with the highly publicized headwinds, still outperformed Evotec and Gingko, which have their own set of problems. In what appears to be a disaster year for the contract research lab industry, this massive drop in share price appears to be correlated with the general retraction of big pharma headcount and layoffs. Fewer orders placed, less revenue, less research done. Hopefully this will not turn into a vicious cycle.

Introducing Pitt BioForge      Hello, LinkedIn community!    Today, we are excited to introduce you to Pitt BioForge. Born from the desire to see more people benefit from the extraordinary potential of the latest generation of precision medicines, we exist to identify and prototype groundbreaking manufacturing innovations that make them accessible to all.    Let us explain further…    We live in an era where precision medicines have the potential to transform lives, offering hope where once there was uncertainty. But as many of us in the healthcare and pharmaceutical industries know, the path to making these breakthroughs widely accessible is fraught with challenges. From scaling manufacturing processes to ensuring the highest standards of quality and consistency, the road can be long, complex and often prohibitively expensive.    We address this with a unique approach. By assembling small project teams bringing together health researchers, engineers, biotech experts, and manufacturing specialists under one roof, we focus on bold yet achievable quantitative objectives working within fixed durations and budgets. By the end of each project, we aim to demonstrate a new capability that was previously considered unattainable. We exist to show what is possible.    Thank you for being part of this journey with us. Together, we can make a real difference. To learn more about us please visit https://lnkd.in/eUdsmF5U     🔍We’re also eager to connect with researchers, pharma professionals, and anyone passionate about the advancement of precision medicines. Let’s work together to turn potential into reality, ensuring that innovative therapies reach those who need them, faster and more reliably than ever before.      #PrecisionMedicine #HealthcareInnovation #Pharma #HCPs #Manufacturingmedicines #Biotech   

The voice of the customer and their feedback is so important to our continuous improvement journey.

Chicago's biotech landscape is evolving and is gaining more recognition as a rising hub for innovation. Major moves in lab space expansion coupled with the opening of the Chan Zuckerberg Biohub are driving growth. While the success of local companies like COUR Pharmaceuticals and Vanqua Bio are helping to prove Chicago’s ability to support groundbreaking R&D. The city currently ranks 10th nationally in biopharma R&D jobs and 3rd in biopharma manufacturing, demonstrating its strength across the value chain. With a collaborative spirit, access to top-tier research institutions, and a focus on work-life balance, Chicago is redefining growth for biotech in the Midwest. Chicago's biotech scene one to watch!

Contract research organisations are essential to the pharma, biotech, and medtech industries, supporting their efforts to test, refine and market their latest drugs and devices. Our latest blog by our Vice President, Theodora Savlovschi-Wicks highlights the top 10 CROs to watch in 2024. Read the full blog to learn how the CRO market is shaping up in 2024: https://lnkd.in/djKpZBxq #GlobalGrowthPartners #LifeSciences #CROs #CROMarket2024

9 Steps to a Successful Lab Move. You’ve seen the signs. You’ve heard the whispers. Just like summer, a lab move is coming. Lab relocations are complex, but can be mastered with careful planning. By following nine main steps, it’s possible to ensure a successful lab move: https://hubs.li/Q02yFfb30 #labmove #science #biotech #pharma #research

SEZs like #ORTamboSEZ drive growth by attracting investment in sectors like agro-processing, pharma, & medical devices. Paving the way for sustainable, local development. Learn more @ www.ortamboSEZ.co.za #EconomicDevelopment #SEZImpact #Precinct2